Navigation Links
Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
Date:1/8/2008

ST. LOUIS, Jan. 8 /PRNewswire-FirstCall/ -- Substantial progress and momentum behind its research-and-development (R&D) pipeline has Monsanto (NYSE: MON) poised to deliver several new blockbuster products to farmers by 2012, company leaders will tell investors today. The remarks will come as part of a series of presentations on the company's R&D pipeline in New York and Boston.

"It's rewarding to see such innovation in the pipeline right now," said Steve Padgette, vice president of biotechnology for Monsanto. "This is the most progress I've seen in my 23 years at the company. Our data demonstrates these cutting-edge innovations can deliver new value to farmers well into the next decade."

As part of the presentations, scheduled over the next two days, Padgette will discuss the progress and momentum behind a number of key projects in the R&D pipeline. Key highlights include:
-- YieldGard VT PRO, one of the primary components of SmartStax

technology, is primed to offer farmers a broader spectrum of insect

control and improved durability when compared with the company's

first-generation corn borer offering. The second-generation corn borer

technology is in Phase IV of the company's R&D pipeline and currently

awaiting regulatory approvals.

-- YieldGard Rootworm III is designed to provide two modes of action for

improved spectrum control and enhanced durability against the corn

rootworm pest. The technology incorporates cutting-edge RNA

interference (RNAi) technology and novel protein identification. RNAi

is a mechanism used naturally by cells to regulate gene expression. By

harnessing this natural machinery, RNAi technology can help plants

protect themselves from insects.

-- Omega-3 enriched soybeans, which are expected to offer a land-based

source of essential Omega-3 fatty acids, continues to demonstrate

comparable consumer acceptability in recent results between SDA soy oil

and conventional soy oil in food uses. The product also continues to

demonstrate solid yield performance when compared to controls.

-- Drought-tolerant cotton, which is designed to minimize risk in cotton

farming by providing yield stability in water stressed environments,

demonstrated strong performance across multiple gene leads. With these

results in hand, Monsanto now believes there are a number of product

leads to create a family of drought traits in cotton.

A live webcast of Monsanto's R&D presentations will be available through Monsanto's web site at: http://www.monsanto.com/investors. Following the live broadcast, a replay of the webcast will be available on the Monsanto web site for two weeks. To access presentation slides and the simultaneous audio webcast of the presentation, visitors may need to download Windows Media Player(TM) prior to listening to the webcast.

To listen to comments from Padgette and Robb Fraley, Monsanto's chief technology officer and executive vice president, on the progress in the pipeline, please visit: http://www.monsanto.com/investors/pipeline/.

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information, please visit: http://www.monsanto.com.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this presentation are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits, including proceedings related to Solutia Inc.; developments related to foreign currencies and economies; successful completion and operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this presentation. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.


'/>"/>
SOURCE Monsanto
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
3. Michigan Life Sciences Pipeline to Kick Off MichBio Expo
4. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
5. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
6. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
7. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
8. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
11. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):